Title: 
Official Title: To direct the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to establish an expedited process for the approval of certain biologics license application supplements for blood centers, and for other purposes.
Number of Sections: 2
Source: versions - Introduced in House
Media Type: text/xml

================================================================================

Section 1:
1.Short titleThis Act may be cited as the Boosting Lifesaving Operations, Opening Donation Centers Act or the BLOOD Centers Act.

Section 2:
2.Expedited process for approval of certain BLA supplements for blood centers (a)EstablishmentNot later than 180 days after the date of enactment of this Act, the Secretary, acting pursuant to section 351(a)(2) of the Public Health Service Act (42 U.S.C. 262(a)(2)), shall establish an expedited process for the approval of a supplemental application submitted by the owner or operator of a blood center seeking to add an apheresis collection device to an existing BLA license at a location not previously licensed for such a device. 
(b)DeadlineUnder the expedited procedure, the Secretary shall approve a supplemental application described in subsection (a) not later than 30 days after the date of submission of the application unless the Secretary makes a showing that there is— (1)a specific concern for the safety, purity, or potency of products produced at the specific location subject to the supplemental application; or 
(2)a systemic failure by the owner or operator to meet standards designed to ensure the continued safety, purity, and potency of products produced at other locations under a biologics license. (c)ApplicabilityThe expedited procedure shall apply with respect to a supplemental application described in subsection (a) if the owner or operator that submits the application— 
(1)holds a biologics license for at least one blood center site; and (2) (A)has been approved for a biologics license at 3 or more Food and Drug Administration registered locations under the biologics license referred to in paragraph (1); or 
(B)is accredited and in good standing for blood collection by an accreditation organization with standards that meet or exceed, as determined by the Secretary, all applicable regulatory requirements for blood collections. (d)DefinitionsIn this section: 
(1)BLAThe term BLA means a biologics license application. (2)Blood centerThe term blood center means a human blood donation center. 
(3)Expedited procedureThe term expedited procedure means the expedited procedure to be established under subsection (a). (4)SecretaryThe term Secretary means the Secretary of Health and Human Services acting through the Commissioner of Food and Drugs.


================================================================================

Raw Text:
119 HR 5791 IH: Boosting Lifesaving Operations, Opening Donation Centers Act
U.S. House of Representatives
2025-10-17
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.



I119th CONGRESS1st SessionH. R. 5791IN THE HOUSE OF REPRESENTATIVESOctober 17, 2025Mr. Wied (for himself, Ms. Schrier, and Mr. Tiffany) introduced the following bill; which was referred to the Committee on Energy and CommerceA BILLTo direct the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to establish an expedited process for the approval of certain biologics license application supplements for blood centers, and for other purposes. 
1.Short titleThis Act may be cited as the Boosting Lifesaving Operations, Opening Donation Centers Act or the BLOOD Centers Act.  2.Expedited process for approval of certain BLA supplements for blood centers (a)EstablishmentNot later than 180 days after the date of enactment of this Act, the Secretary, acting pursuant to section 351(a)(2) of the Public Health Service Act (42 U.S.C. 262(a)(2)), shall establish an expedited process for the approval of a supplemental application submitted by the owner or operator of a blood center seeking to add an apheresis collection device to an existing BLA license at a location not previously licensed for such a device. 
(b)DeadlineUnder the expedited procedure, the Secretary shall approve a supplemental application described in subsection (a) not later than 30 days after the date of submission of the application unless the Secretary makes a showing that there is— (1)a specific concern for the safety, purity, or potency of products produced at the specific location subject to the supplemental application; or 
(2)a systemic failure by the owner or operator to meet standards designed to ensure the continued safety, purity, and potency of products produced at other locations under a biologics license. (c)ApplicabilityThe expedited procedure shall apply with respect to a supplemental application described in subsection (a) if the owner or operator that submits the application— 
(1)holds a biologics license for at least one blood center site; and (2) (A)has been approved for a biologics license at 3 or more Food and Drug Administration registered locations under the biologics license referred to in paragraph (1); or 
(B)is accredited and in good standing for blood collection by an accreditation organization with standards that meet or exceed, as determined by the Secretary, all applicable regulatory requirements for blood collections. (d)DefinitionsIn this section: 
(1)BLAThe term BLA means a biologics license application. (2)Blood centerThe term blood center means a human blood donation center. 
(3)Expedited procedureThe term expedited procedure means the expedited procedure to be established under subsection (a). (4)SecretaryThe term Secretary means the Secretary of Health and Human Services acting through the Commissioner of Food and Drugs.